Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
subsequent superior/inferior supportive care, lifestyle changes, and/or use of additional therapies). In fact, the FDA estimates that the accelerated approval program is responsible for access to life-saving anti-cancer therapies a median of 3.4 years before they would have been available otherwise.
40 
Let's personalize your content